Home  |  Site Map  |  Contact Us  |  
Search

   
   

Corporate Profile

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders.  XenoPort is currently commercializing Horizant® (gabapentin enacarbil) Extended-Release Tablets, its first approved product in the United States, and developing a novel fumaric acid ester product candidate, XP23829, as a potential treatment for relapsing-remitting multiple sclerosis and/or psoriasis.  Regnite is being marketed in Japan by Astellas Pharma Inc.  XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease.

PDF XenoPort Investor Presentation – November 2014    1.8 MB Add to Briefcase

Stock Information

NASDAQ : XNPT

$8.20 + 0.29
Dec 19, 2014 4:00 PM ET
Delayed at least 20min., by eSignal.

Stock price graph